Mirador Therapeutics closed a $250 million Series B to scale development of precision medicines for immune diseases and signaled consideration of an IPO later this year. The company told Endpoints News the financing will underwrite clinical and translational work as it advances lead programs in immunology. Mirador framed the raise as capitalization for rapid growth and potential public-market readiness if clinical data validate its approach.